This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
HIV/AIDS	Histone deacetylase (HDAC); CTLA-4 (CD152); BET bromodomain proteins; HIV env	<p>Mouse studies suggest combining broadly neutralizing antibodies (bNAbs) and inducers of HIV transcription could help treat HIV infection. In humanized mouse models of latent HIV infection, a combination of three bNAbs against HIV env epitopes plus induction of HIV transcription with vorinostat, an anti-CD152 mAb and a BET bromodomain protein inhibitor decreased the number of animals that showed viral rebound after treatment discontinuation compared with the three bNAbs alone or in combination with any single viral inducer. Next steps could include optimizing the bNAb-viral inducer combinations.</p> <p>Merck & Co. Inc. and Taiho Pharmaceutical Co. Ltd. market Zolanza vorinostat, an HDAC inhibitor, to treat cutaneous T cell lymphoma. The partners also have the drug in Phase III testing to treat mesothelioma and multiple myeloma and in Phase I testing to treat brain cancer.</p> <p>Merck also has the drug in Phase I/II testing to treat graft-versus-host disease (GvHD).</p> <p>Bristol-Myers Squibb Co. markets the CD152-targeting antibody Yervoy ipilimumab to treat melanoma. The mAb also is in Phase II/III testing to treat other cancers.</p> <p>Pfizer Inc. has tremelimumab in Phase II testing to treat liver cancer, non-small cell lung cancer (NSCLC) and solid tumors. The mAb also is in Phase I testing to treat melanoma and prostate cancer.</p> <p>SciBX 7(35); doi:10.1038/scibx.2014.1045 Published online Sept. 11, 2014</p>	Patent and licensing status unavailable	<p>Halper-Stromberg, A. <i>et al. Cell</i>; published online Aug. 14, 2014; doi:10.1016/j.cell.2014.07.043</p> <p>Contact: Michel C. Nussenzweig, The Rockefeller University, New York, N.Y. e-mail: nussen@rockefeller.edu</p>